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_ ... ADAPTIVE IMMUNITY 
• Secondary defense 
• Delayed 
• Antigen-specific 













• Primary defense 
• Immediate 
• Non-specific 
• Does not result in memory 
Cell mediated immunity: 
Mediated by cytotoxic T 
lymphocytes which destroy 
viral infected cells , transplant 
cells , some tumor cells 
Humoral immunity: 
Mediated by B cells/ 
Plasmacytes. Antibodies bind 
specific antigens, signals other 
cells to engulf and remove that 








Nai·ve Plasma Memory 
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- JC virus 
- Measles 





- Epstein-Barr virus 
- Cytomegalovirus 
Eye infections 




- Influenza virus, 




syncytial vi rus 
Cardiovascular-----'"----4-~::' - Adenovirus 
- Coxsackie B virus 
Hepatitis,-------' 
- Hepatitis virus 
types A, B, C, D, E 
Skin infections----..;;... 
- Varicella zoster virus 
- Human herpesvirus 6 
• Smallpox 
- Molluscum contagiosum 
- Human papillomavirus 







































Diabetes lype I 






Blood and Saliva Collection- ISS












Return Ambient – 45h Delay
Frozen on Orbit
• Innate immunocyte function dysregulated during spaceflight
• Plasma cytokine concentrations are altered in astronauts
• Astronauts experience persistent reactivation of latent herpesviruses, biomarker of 
reduced immunity
• Astronauts demonstrate elevated stress hormones and dysregulated circadian 
rhythms during spaceflight
• Astronauts have some degree of clinical incidence, primarily dermatitis, allergy and 
infections
• Dermatitis may be associated with viral etiology
• Some crew experience persistent symptoms requiring prolonged management
• Peripheral leukocyte distribution in astronauts is 
relatively normal
• T cell, NK cell function is inhibited by microgravity
• T cell function is reduced in astronauts; appears to be 
a shift in the activation threshold
• NK cells are disarmed, reduction in lytic molecule 
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Early Mid Late R+O 
T cell 
One method of the " co-stimulation" 
needed to activate T cells . II the T cell 
falls to receive "signal two", It dies by 
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CD71 (Target Cells) 
1X PBMC 
(NK:target = 1 :6) 
.. ,~----------~ 




















Data expressed as % change from 
baseline (L-180). NK-cell function did 














Spaceflight Reduces NK 
Cell Function
NK Cell Function
0 180 0 180 
.. .. 
~ 160 ~ 160 
s 140 s 140 
~ 120 ~ 120 
"" "" .. .. ! 100 ! 100 
.; 80 .; 80 u u 
~ ~ 
CII 60 CII 60 C. C. 
iS 40 iS 40 
.. .. 










.; 80 u 
~ 
60 CII 60 C. 
iS 40 iS 40 
.. .. 
z 20 z 20 
0 0 








IL-1α IL-1ra IFNγ G-CSF CCL2/MCP-1
IL-1β IL-2 GM-CSF CCL3/MIP-1 alpha 
TNFα IL-17 FGF basic CCL4/MIP-1 beta 
IL-6 IL-4 Tpo CCL5/RANTES
IL-8 IL-5 VEGF CXCL5/ENA-78
IL-10
Plasma Cytokine Analysis








• Food peptides 
•Allergens 
• Medications 
• Auto antigens 
ThO: NaiVe T cells 
Th: Helper T cells 
Treg: Regulatory T cells 
IL: Interleukin 
Th17 
• Extracellular bacteria 





TNF-a: Tumor necrosis factor-alpha 
IFN-y: Interferon-gamma 
Treg 
• Immune tolerance 
• Lympocyte homeostasis TGF-p: Transforming growth factor-beta 






• Cell,mediated Immunity and 
inflammation 
• Intracellular pathogens 
• Viruses, bactena 
• Autoimmunity 
• Inflammation 
• Antibody-mediated Immunity 
• Extracellular parasites 
• Asthma, allergy 
Cytokine
IL-1a 0.3 ± 0.1 0.4 ± 0.3 0.9 ± 0.5 0.3 ± 0.1 2.4 ± 1.9 0.6 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
IL-1b 0.4 ± 0.1 0.7 ± 0.3 1.5 ± 1.0 0.8 ± 0.3 0.9 ± 0.5 1.3 ± 0.9 1.1 ± 0.8 0.5 ± 0.2 0.8 ± 0.3
TNFa 1.4 ± 0.1 1.4 ± 0.1 3.2 ± 1.0 2.0* ± 0.3 2.1 ± 0.4 2.2 ± 0.5 2.0 ± 0.4 1.3 ± 0.1 1.7 ± 0.2
IL-6 0.3 ± 0.1 0.3 ± 0.1 0.5 ± 0.2 0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 1.1* ± 0.2 0.3 ± 0.1
IL-8 2.0 ± 0.3 2.1 ± 0.3 8.1* ± 2.1 7.9* ± 2.3 7.7* ± 1.7 7.3* ± 2.1 6.9* ± 2.3 2.1 ± 0.3 2.3 ± 0.4
IL-1ra 383 ± 40 370 ± 35 567* ± 65 563* ± 80 638* ± 101 728* ± 129 661* ± 85 682* ± 118 568 ± 146
IFNg 0.8 ± 0.2 0.8 ± 0.2 0.6 ± 0.1 0.7 ± 0.2 0.8 ± 0.2 0.9 ± 0.2 0.7 ± 0.3 0.5* ± 0.1 0.7 ± 0.2
IL-2 2.2 ± 0.6 1.8* ± 0.5 1.7* ± 0.5 2.6 ± 0.8 2.4 ± 0.7 2.5 ± 0.7 2.4 ± 0.8 2.4 ± 0.7 2.7 ± 0.9
IL-17 1.3 ± 0.3 1.1 ± 0.3 0.9 ± 0.2 1.0 ± 0.2 1.1 ± 0.3 1.1 ± 0.2 0.9 ± 0.3 0.9* ± 0.2 0.9 ± 0.2
IL-4 0.3 ± 0.1 0.5 ± 0.3 3.2 ± 1.7 0.3 ± 0.2 1.4 ± 0.7 2.1 ± 1.5 1.6 ± 1.2 0.4 ± 0.2 0.2 ± 0.1
IL-5 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
IL-10 0.2 ± 0.0 0.2 ± 0.1 0.4 ± 0.2 0.2 ± 0.0 0.2 ± 0.0 0.4 ± 0.2 0.2 ± 0.0 0.3 ± 0.1 0.4 ± 0.1
G-CSF 7.2 ± 1.9 7.0 ± 1.7 7.0 ± 1.8 4.5 ± 0.8 7.6 ± 2.0 14.7 ± 7.8 9.8 ± 3.2 10.3* ± 2.8 5.9 ± 1.4
GM-CSF 0.6 ± 0.3 0.3 ± 0.1 3.4 ± 1.9 1.9* ± 0.8 2.7 ± 1.3 2.8 ± 1.9 2.7 ± 1.9 0.7 ± 0.4 0.7 ± 0.4
FGFb 13.7 ± 5.4 15.4 ± 5.7 11.8 ± 3.3 21.9 ± 5.7 18.5 ± 4.9 12.1 ± 3.7 10.8 ± 2.7 11.7 ± 3.8 12.3 ± 4.3
Tpo 140 ± 16 146 ± 18 184* ± 18 189* ± 30 191* ± 22 196* ± 28 221* ± 24 141 ± 17 133 ± 16
VEGF 5.8 ± 0.9 6.2 ± 1.3 10.9* ± 1.9 15.8* ± 4.9 11.3* ± 1.7 12.5* ± 3.5 11.7* ± 1.9 5.1 ± 1.0 5.5 ± 0.9
CCL2/MCP-1 72.4 ± 6.8 78.5 ± 7.7 71.7 ± 5.4 66.0 ± 5.8 77.0 ± 7.0 84.0 ± 7.0 87.0 ± 7.7 124* ± 18.1 90* ± 7.5
CCL3/MIP-1a 20.3 ± 5.0 16.6 ± 5.0 25.9 ± 8.1 15.0 ± 4.4 19.1 ± 6.6 22.7 ± 7.4 21.7 ± 8.6 19.4 ± 6.3 18.1 ± 5.5
CCL4/MIP-1b 16.2 ± 2.2 16.7 ± 2.7 22.3* ± 2.9 20.2* ± 2.5 22.2* ± 2.8 24.3 ± 5.1 21.6* ± 3.3 17.3 ± 2.3 19.3 ± 4.0
CCL5/RANTES 3613 ± 263 3292 ± 246 3618 ± 202 3746 ± 195 3575 ± 185 3818 ± 217 4030 ± 202 3410 ± 266 3623 ± 219
CXCL5/ENA-78 231 ± 58 367 ± 219 2065* ± 371 1858* ± 310 2015* ± 360 1749* ± 309 1860* ± 388 190 ± 48 202 ± 55
L-180 L-45
Spaceflight
FD180 R+0 R+30FD120FD30 FD60FD15
Table 2:  Mean plasma cytokine levels for ISS astronauts before, during, and following spaceflight. Data are expressed as 
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Reactivation in 65% 
of the crewmembers 
-200 -100 0 100 
Sample Collection Days 
200 300 
Latent Herpesvirus
Zoster Patients (n=42)     100% positive
Astronauts (n=23)            2-3 samples per crew= 59 total samples – 29/59 positive (49%)
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Allergic Reaction 1 0.06
Anaphylaxis 0 ---
Upper Respiratory Infection (combination of rhinitis, nasal 
stuffiness and sneezing)
5 0.301
Eye Infection 0 ---
Herpes Zoster 5 0.301
Otitis Media/Externa (ear pain, or ear stuffiness+congestion) 17 1.022
Pharyngitis (sore throat) 1 0.06
Sepsis 0 ---
Sinus Infection 0 ---
Skin Infection (including scalp pruritis, pus forming wounds on 
wrist, finger)
5 0.301
Skin Rash/Hypersensitivity (including skin conditions such as 
tinea versicolor, dermatitis, rosacea) 
23 1.383
Urinary Tract Infection 1 0.06
Malignancies* 0 ---
Autoimmunity* 0 ---
Infections, Other*# 11 0.666
Total: 69 4.18
Medical Conditions
Table II:  Incidence data, ISS Program, Expeditions 1 to 28/29; 37 ISS crewmembers; 
total flight duration 6072 days/16.63 person years.  
Source JSC Epidemiology Group: A. Babiak-Vazquez, Sara Mason and Jessica Garcia. 
*Indicates additional conditions or symptoms categorized, beyond the original 13 IMM conditions.  
#Additional infectious processes not characterized within other categories such as lymphadenitis, 
lymphadenopathy, mild fever and intestinal problems with such symptoms as diarrhea, excessive 
intestinal gas and bloating.
Clinical Incidence
Case Study ISS Astronaut
-Allergic symptoms in a non-allergic
subject
-Subject developed an Atopic
Dermatitis on mission day 17
-Rash was bothersome, at times
severe
-A variety of treatments employed
-At times the medications of choice
were exhausted
-Rash never resolved for the duration of the mission, although it was 
successfully managed to a tolerable level
-Rash spikes generally correlated well with operational stressors
-Research findings confirm immune dysregulation persisted for the duration 
of the mission
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Clinical Incidence
• Rashes were observed to occur in the 
following locations:  scalp, face, neck, 
chest, back, trunk, abdomen, arms and 
hands. 
• The appearance of the rashes 
generally consists of bumps/nodules 
and/or small brown scaly patches, 
with or without petechiae, 
redness/hyperemia and itching.   
Clinical Incidence
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                     MEDICATIONS KEY
Clinical Incidence
The Herpes Simplex Virus type-1 reactivation associated with a 
case of persistent dermatitis during Spaceflight
43rd International Herpesvirus Workshop;  Vancouver, Canada;  July 21-25, 2018
Clinical Incidence
Tertiary infection using the cells and media from the secondary infection. 





(CT-22; 5.4x10(6) copies per ng total DNA)
Positive
(CT-15; 1.4x10(9) copies per ng total DNA)
Negative
VZV Negative N/A N/A
HSV1
Positive




• Peripheral leukocyte distribution in astronauts is relatively normal
• T cell function is inhibited by microgravity
• T cell function is reduced in astronauts; appears to be a shift in the 
activation threshold
• NK cell function is reduced in astronauts
• NK cells are disarmed, reduction in lytic molecule content
• B cell function in astronauts appears unaltered (limited data)
• Plasma cytokine concentrations are altered in astronauts
• Astronauts experience persistent reactivation of latent 
herpesviruses, biomarker of reduced immunity
• Astronauts demonstrate elevated stress hormones and dysregulated 
circadian rhythms during spaceflight
• Astronauts have some degree of clinical incidence, primarily 
dermatitis, allergy and infections
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Immune System Dysregulation 
During Spaceflight: Potential 
Countermeasures for Deep Space 
Exploration Missions 
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Recent studies have established that dysregulation of the human immune system and 
the reactivation of latent herpesviruses persists for the duration of a 6-month orbita 
spaceflight. It appears certain aspects of adaptive immunity are dysregulated during 
flight, yet some aspects of innate immunity are heightened. Interaction between adap-
tive and innate immunity also seems to be altered. Some crews experience persistent 
hypersensitivity reactions during flight. This phenomenon may, in synergy with extended 
Immune 
Countermeasures
Potential Immunologic Countermeasures for Deep Space Missions 
Precision 
Countermeasures 
Pre-Mission Immunological Screen 
Pre-mission immunological screen may include: 
Personal history of allergy/hypersensitivity, etc. 
Medication history (antihistamines, etc.) 
Leukocyte distribution (NK cell subsets) 
Cytokine concentration: Th1/fh2, etc. 
Allergy screen, patch testing 
Latent herpesvirus sero-positivity 
Pathogen-Specific Mitigations 
Antiviral (VZV) vaccination 
General Specific 
Countermeasures Countermeasures 
Already in Place/Will be Optimized 




Diet optimized to reduce nutrient deficiency 
Functional foods/bioactive compounds 
Nutritional supplements: 




Optimized exercise equipment 
Radiation shielding 
Multisystem Countermeasures 
Optimized exercise regimen 
Adequate sleep schedules 
Psychological support - family 
communication 










• Omega 3 fatty acids 
• Supplemental nucleotides 
• AHCC 
• Pegylated-lL-2 
In-flight Monitoring of 
Immune Parameters? 
PRE-FLIGHT LAUNCH TRANSIT PHASE CIS-LUNAR STATION/ 
LUNAR SURFACE OPS 
MARS FLYBY or ORBIT/ 
MARS SURFACE OPS 
Spaceflight 
Immunologists
NASA JSC
Immunology/Virology
Laboratory
